Abstract 1003P
Background
Multimodal approach, a combination of various treatment modalities, has emerged as a potential approach for treating uHCC. It is utilized to help relieve tumor burden, slow progression, and provide survival benefits to patients. However, controversies remain in using a multimodal approach in the management of uHCC, and is still debatable. This study aims to evaluate the efficacy and safety of triple combination therapy composed of Transarterial chemoembolization (TACE), TKI, and ICI compared to dual combination therapy (TACE+TKI, TKI+ICI).
Methods
Eligible studies published before March 30, 2023 were retrieved. Outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and occurrence of adverse events (AEs). Literature search was done using through PubMed, Embase, and Cochrane Library. Risk of bias assessment was done using ROBINS-I tool.
Results
Thirteen retrospective studies were included representing 1005 patients with uHCC. There was low to moderate bias among the studies. Triple combination therapy was associated with a significant improvement in survival compared to dual combination therapy: median OS, pooled HR 0.46 (95% CI: 0.39-0.54, p<0.00001) and median PFS, pooled HR 0.41 (95% CI: 0.28-0.61, p<0.00001). Triple combination therapy was also associated with a significant increase in tumor response compared to dual combination therapy: ORR, pooled RR 1.76 (95% CI: 1.51-2.06, p<0.00001), and DCR, pooled RR 1.36 (95% CI 1.24-1.49, p-<0.00001). However, triple combination therapy had a higher risk of adverse events compared to dual combination therapy, pooled RR 1.49 (95% CI: 1.19, 1.86, p=0.0004). There was no significant heterogeneity found among the studies included.
Conclusions
Triple combination therapy was associated with significantly better outcomes but higher risk of adverse events than dual combination therapy in patients with uHCC so careful consideration of the risks and benefits must be done before initiating treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18